Omeros (OMER) Gross Margin (2014 - 2026)

Omeros' (OMER) quarterly Gross Margin came in at 94.07% in Q1 2026, down 4.88% quarter-over-quarter from 98.89% in Q3 2021.

Omeros (OMER) Gross Margin (2014 - 2026) Analysis & Trends

Omeros has disclosed Gross Margin across 9 years of filings, most recently posting 94.07% for Q1 2026.

Gross Margin for Q1 2026 came in at 94.07%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 98.16% (down 66.0% YoY), and the FY2020 annual result was 98.78%, down 45.0% from the prior year.
Gross Margin came in at 94.07% for Q1 2026 at Omeros, down from 98.89% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 94.07% in Q1 2026 to a low of 94.07% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	79.04%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	86.85%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Omeros	737.87 Mn	602.55 Mn	9.31 Mn	94.07%

Historic Data

Download Data

Date	Value
Mar 31, 2026	94.07%
Sep 30, 2021	98.89%
Jun 30, 2021	98.81%
Mar 31, 2021	98.75%
Dec 31, 2020	99.18%
Sep 30, 2020	98.46%
Jun 30, 2020	98.91%
Mar 31, 2020	98.87%
Dec 31, 2019	98.80%
Sep 30, 2019	99.07%
Jun 30, 2019	99.79%
Mar 31, 2019	99.40%
Dec 31, 2018	99.29%
Sep 30, 2018	99.22%
Jun 30, 2018	92.99%
Mar 31, 2018	87.22%
Dec 31, 2017	96.62%
Sep 30, 2017	99.15%
Jun 30, 2017	99.08%
Mar 31, 2017	97.79%